These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 36283859)

  • 1. Barriers for the evaluation of advanced therapy medicines and their translation to clinical practice: Umbrella review.
    Aguilera-Cobos L; Rosario-Lozano MP; Ponce-Polo A; Blasco-Amaro JA; Epstein D
    Health Policy; 2022 Dec; 126(12):1248-1255. PubMed ID: 36283859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Technology forecast: advanced therapies in late clinical research, EMA approval or clinical application via hospital exemption.
    Eder C; Wild C
    J Mark Access Health Policy; 2019; 7(1):1600939. PubMed ID: 31069029
    [No Abstract]   [Full Text] [Related]  

  • 3. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.
    Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N
    Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-marketing authorisation safety and efficacy surveillance of advanced therapy medicinal products in Brazil, the European Union, the United States and Japan.
    Gomes KLG; da Silva RE; da Silva JB; Bosio CGP; Novaes MRCG
    Cytotherapy; 2023 Oct; 25(10):1113-1123. PubMed ID: 37436339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient access to and ethical considerations of the application of the European Union hospital exemption rule for advanced therapy medicinal products.
    Cuende N; Ciccocioppo R; Forte M; Galipeau J; Ikonomou L; Levine BL; Srivastava A; Zettler PJ
    Cytotherapy; 2022 Jul; 24(7):686-690. PubMed ID: 35545453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States.
    Iglesias-Lopez C; Obach M; Vallano A; Agustí A
    Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Call for More Effective Regulation of Clinical Trials with Advanced Therapy Medicinal Products Consisting of or Containing Genetically Modified Organisms in the European Union.
    Beattie S;
    Hum Gene Ther; 2021 Oct; 32(19-20):997-1003. PubMed ID: 33843251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced therapy medicinal product manufacturing under the hospital exemption and other exemption pathways in seven European Union countries.
    Coppens DGM; Hoekman J; De Bruin ML; Slaper-Cortenbach ICM; Leufkens HGM; Meij P; Gardarsdottir H
    Cytotherapy; 2020 Oct; 22(10):592-600. PubMed ID: 32563611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EU Regulatory Pathways for ATMPs: Standard, Accelerated and Adaptive Pathways to Marketing Authorisation.
    Detela G; Lodge A
    Mol Ther Methods Clin Dev; 2019 Jun; 13():205-232. PubMed ID: 30815512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory Aspects for Approval of Advanced Therapy Medicinal Products in the EU.
    Fürst-Ladani S; Bührer A; Fürst W; Schober-Ladani N
    Handb Exp Pharmacol; 2024; 284():367-387. PubMed ID: 37017789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methodological Characteristics of Clinical Trials Supporting the Marketing Authorisation of Advanced Therapies in the European Union.
    Iglesias-Lopez C; Agustí A; Vallano A; Obach M
    Front Pharmacol; 2021; 12():773712. PubMed ID: 34916948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Environmental risk assessment of advanced therapies containing genetically modified organisms in the EU.
    Whomsley R; Palmi Reig V; Hidalgo-Simon A
    Br J Clin Pharmacol; 2021 Jun; 87(6):2450-2458. PubMed ID: 33600022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hurdles in clinical implementation of academic advanced therapy medicinal products: A national evaluation.
    de Wilde S; Veltrop-Duits L; Hoozemans-Strik M; Ras T; Blom-Veenman J; Guchelaar HJ; Zandvliet M; Meij P
    Cytotherapy; 2016 Jun; 18(6):797-805. PubMed ID: 27068764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Current State of Advanced Therapy Medicinal Products in the Czech Republic.
    Kočí Z; Boráň T; Krůpa P; Kubinová Š
    Hum Gene Ther Clin Dev; 2018 Sep; 29(3):132-147. PubMed ID: 29869533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced therapy medicinal products: current and future perspectives.
    Hanna E; Rémuzat C; Auquier P; Toumi M
    J Mark Access Health Policy; 2016; 4():. PubMed ID: 27123193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Academic cell therapy facilities are challenged by European regulation on advanced therapy medicinal products].
    Chabannon C; Sabatier F; Rial-Sebbag E; Calmels B; Veran J; Magalon G; Lemarie C; Mahalatchimy A
    Med Sci (Paris); 2014 May; 30(5):576-83. PubMed ID: 24939546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Market access pathways for cell therapies in France.
    Rémuzat C; Toumi M; Jørgensen J; Kefalas P
    J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe.
    Farkas AM; Mariz S; Stoyanova-Beninska V; Celis P; Vamvakas S; Larsson K; Sepodes B
    Front Med (Lausanne); 2017; 4():53. PubMed ID: 28560211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory landscape for cell therapy--EU view.
    McBlane JW
    Biologicals; 2015 Sep; 43(5):433-6. PubMed ID: 25997566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hurdles of environmental risk assessment procedures for advanced therapy medicinal products: comparison between the European Union and the United States.
    Iglesias-Lopez C; Obach M; Vallano A; Agustí A; Montané J
    Crit Rev Toxicol; 2019 Aug; 49(7):580-596. PubMed ID: 31846383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.